Better Therapies for Patients
Better Therapies for patients
We make a difference in people's health – and in your portfolio
Grow your brand with added value and innovative medicines!
Whether it´s fewer side effects, a better API absorption or a personalized drug dispensing device, we at Tiefenbacher Pharmaceuticals believe that there are always new ways of smart medicines which better deliver on patients´ needs. Our highly experienced research & development and innovation managers continuously strive for new pharmaceutical technologies and products – both in the field of generic and innovative formulations. This pioneer spirit is driven by our curiosity – the curiosity of each of our employees dedicated to make patients´ life better.
Our own laboratories with up-to-date technologies and our exclusive global network of development partners enable us to cover all major therapeutics and innovative dosage forms. We succeed in developing tablets, capsules, modified release formulations, oral and ophthalmic solutions as well as special technologies like patches, injectables or personalized devices. Furthermore, we are committed to drive for growth and innovation with a well-defined and specialized portfolio of highly potent drug formulations.
Our Expertise
Our success factors for breakthrough research and development
We focus on discovering value added and innovative drugs that can change the practices of medicine by using groundbreaking science and technology. Our capabilities span a wide range of development technologies and specialties — all backed by comprehensive industry knowledge and experience.
CREATING BETTER THERAPIES THROUGH PRODUCT DIFFERENTIATION AND INNOVATION
Value added and innovative medicines which will set you apart
Product differentiation and innovation are a core business at Tiefenbacher Pharmaceuticals. We believe that there are always new ways of smart medicines which better deliver on patients` needs. This includes less side effects, a better API absorption, additional product strengths, new fix-dose combinations, or a personalized dosing with an innovative drug device – just to name a few examples of our distinctive product features and innovations. We are constantly developing new product solutions for reaching an unique selling proposition in the market and bringing added value to patients – always with a patient-centric approach.
For more information about our differentiated and innovative product pipeline, please contact us – by filling out the contact form below on this webpage, or please send an email to info@tiefenbacher.com. We are looking forward to share these licensing opportunities based on a CDA and the specific marketing & sales requirements.
Value Added Products
- Once-daily products for better posology
- More patient-friendly dosage forms than the innovator
- Prodrugs with better side-effect profile (e.g. to make MS therapy safer)
- Prodrug with 5 years of IP advantage
- Extended-release formulations with less side effects
- New suitable dosage strengths for better treatment options
- Fix-dose combinations
Innovative Products
- Digital platform for new drug /device combination for personalized treatment
- New orphan indication for known molecule
- New OTC products
- First NCE-approved drug in Europe
TNew Development block at TIefenbacher Laboratories in India
Transforming pharmaceutical ideas into real-world therapies
At our new state-of-the-art R&D center in Hyderabad, India, we translate pharmaceutical innovation into scalable, regulatory-compliant products for global markets. Equipped with FDA-approved infrastructure and advanced technologies, we develop both affordable and value-added formulations.
- Major dosage forms – tablets, capsules, and liquids
- Most modern techniques incl. in-house XRD Crystallography, IVIVC WinNonlin simulation tools, Malvern particle size and Nitrosamine testing
- Strict GLP/GMP standards and international guidelines (ICH, EU, USFDA)
- ISO 14001:2014 and ISO 18001:2025 certifications
New Generation of Pharmaceuticals
Next-level R&D for highly potent drug formulations
With our new high-potent lab in Hyderabad, Tiefenbacher Group enters a new era of innovation. These next-generation pharmaceuticals, highly potent and effective at extremely low doses are developed under the highest containment and quality standards. We cover the full development process: from early-stage research to in-house commercial manufacturing.
- Development of highly potent oncology drugs up to OEB 5
- Tablets and capsules
- Contained equipment with closed material transfer system using containment charging & discharging compliant to OEL 5 level
- Already 25 leading highly potent drugs in pipeline
We are best practice
First NCE Approval for innovative sleeping medicine
In 2019 AET successfully gained the first European NCE approval for an advanced drug being used to treat the symptoms of insomnia in a better and safer way. Studies have shown that our sleeping aid has the following main advantages compared to other sedative drugs: Our product has a lower dosage and, based on available studies, can be used for a longer period of time. Other sleeping pills may only be used for a maximum of two weeks. The innovative drug has been studied in a variety of clinical settings involving primary insomnia and insomnia secondary to various chronic conditions such as rheumatoid arthritis, generalised anxiety disorder, and major depressive illness. The results across studies in adults are consistent and demonstrate shorter sleep latency, longer sleep time, and less wakening after the onset of sleep compared to placebo. Furthermore, the study program revealed that our sleeping medicine provides safety benefits resulting from lower morning serum levels.
The product has been launched in several European countries. With this first marketing authorization, AET enables thousands of patients in Europe suffering from insomnia a better and safer therapy – sustainably improving their quality of life.